Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Non-A, non-B hepatitis: hepatitis C].

M C de Moura1

  • 1Serviço de Gastrenterologia, Faculdade de Medicina de Lisboa.

Acta Medica Portuguesa
|July 1, 1990
PubMed
Summary

Non-A, non-B hepatitis (NANB) frequently leads to chronic hepatitis and cirrhosis. The identification of Hepatitis C virus (HCV) offers a pathway to detect and prevent transfusion-associated NANB hepatitis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lectins as antimicrobial agents.

Journal of applied microbiology·2018
Same author

[Autoimmune cholangiopathy].

Acta medica portuguesa·2001
Same author

Alpha-interferon improves liver fibrosis in chronic hepatitis C: clinical significance of the serum N-terminal propeptide of procollagen type III.

Digestive diseases and sciences·2001
Same author

Hepatic stellate cell activation occurs in nonalcoholic steatohepatitis.

Hepato-gastroenterology·2001
Same author

Apoptotic cell death does not parallel other indicators of liver damage in chronic hepatitis C patients.

Journal of viral hepatitis·2000
Same author

Long-term gallbladder stone recurrence and risk factors after successful lithotripsy.

European journal of gastroenterology & hepatology·2000

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Context:

  • Non-A, non-B hepatitis (NANB) is a significant cause of chronic liver disease.
  • Chronic NANB hepatitis progresses to cirrhosis in up to 20% of cases.
  • Transfusion-associated and sporadic NANB hepatitis are common clinical challenges.

Purpose:

  • To report the identification of the agent responsible for NANB hepatitis.
  • To describe the characteristics of the Hepatitis C virus (HCV).
  • To discuss the serologic detection and clinical implications of HCV infection.

Summary:

  • Hepatitis C virus (HCV), a single-stranded RNA virus, was identified in 1988.
  • Serologic evidence of HCV infection is found in a majority of transfusion-associated hepatitis cases.
  • Antibody to HCV (anti-HCV) is detected in various liver conditions, including chronic hepatitis B and alcoholic cirrhosis.

Impact:

  • The identification of HCV enables serologic testing for transfusion safety.
  • Screening blood donations for anti-HCV is expected to decrease transfusion-associated NANB hepatitis.
  • Further advancements in HCV antigen detection, like PCR, are needed.

Related Experiment Videos